Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH)

Valuation and Earnings

This table compares Eagle Pharmaceuticals and Bio-Path”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55 million	0.04	$35.64 million	$1.18	0.59
Bio-Path	N/A	N/A	-$16.08 million	($1.82)	-0.05

Eagle Pharmaceuticals has higher revenue and earnings than Bio-Path. Bio-Path is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eagle Pharmaceuticals and Bio-Path’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Bio-Path	N/A	-2,842.40%	-337.48%

Institutional and Insider Ownership

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500.

Summary

Eagle Pharmaceuticals beats Bio-Path on 9 of the 9 factors compared between the two stocks.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.